By Michael RitchiePublished June 05, 2018 12:57:06Canada’s largest pharmaceutical company has agreed to donate $5 million to a group that works to advance the development of genetically engineered cancer drugs.
The salk International Institute for Biomedical Research, or salkIBIR, announced Friday that it would be donating $1 million to the Canadian Cancer Society.
It’s a small sum compared to what the institute has raised, but salk says that will enable it to further develop its cancer drug candidates.
The Canadian Cancer Research Foundation is an industry-funded non-profit dedicated to advancing cancer research in Canada.
It has received $100 million from the federal government since 2008.
The Canadian Society for Cancer Research received $35 million in funding in the same period.
salk IBIR is not a member of either society.
sankr had been working with the Canadian Society of Cancer Research to develop a drug for colorectal cancer.
The project, called R2I3, is an engineered form of a protein called RAR that can be used in a variety of cancer treatments.
Scientists have found that cancer cells use RAR to attack and destroy cancerous cells, but it is difficult to develop drugs that do the same.
The first of a type of RAR, known as CRISPR-Cas9, has been approved for use in colorecctal and breast cancer.
sRAR has also been shown to work against several other types of cancer.